Human immunodeficiency virus type 1 neutralization by plasma from B or F genotype infected individuals

• Published in: Memórias do Instituto Oswaldo Cruz 2005-02, Vol.100 (1), p.85-89
• Main Authors: Bongertz, V, Teixeira, S L M, Grinztejn, B, Pilotto, J H, Veloso, V G, Morgado, M G, Bastos, F I, Ouverney, E P
• Format: Article
• Language: English
• Subjects: AIDS Vaccines; Antibody Specificity - genetics; Antibody Specificity - immunology; Brazil; Cross Reactions - genetics; Cross Reactions - immunology; Female; Genotype; HIV Antibodies - immunology; HIV Antigens - immunology; HIV Envelope Protein gp120 - genetics; HIV Envelope Protein gp120 - immunology; HIV Infections - immunology; HIV Infections - virology; HIV-1 - genetics; HIV-1 - immunology; Human immunodeficiency virus 1; human immunodeficiency virus type 1; human immunodeficiency virus type 1 - neutralization - genotype - Brazil; Humans; Male; neutralization; Neutralization Tests - methods; PARASITOLOGY; Peptide Fragments - genetics; Peptide Fragments - immunology; TROPICAL MEDICINE
• ISSN: 1678-8060; 0074-0276; 0074-0276; 1678-8060
• DOI: 10.1590/S0074-02762005000100016

Anti-human immunodeficiency virus type 1 (HIV-1) "binding antibodies" (antibodies capable of binding to synthetic peptides or proteins) occur throughout HIV-1 infection, are high-titered and highly cross-reactive, as confirmed in this study by analyzing plasma from B and F genotype HIV-1 infected individuals. Plasma from individuals infected with clade F HIV-1 displayed the most frequent cross-reactivity, in high titers, while Bbr plasma showed much higher specificity. Similarly, neutralization of a reference HIV-1 isolate (HIV-1 MN) was more frequently observed by plasma from F than B genotype infected individuals. No significant difference was seen in neutralization susceptibility of primary B, Bbr or F clade HIV-1 by plasma from individuals infected with the classical B (GPGR) or F HIV-1, but Bbr (GWGR) plasma were less likely to neutralize the F genotype primary HIV-1 isolates. The data indicate that both B and F genotype derived vaccines would be equally effective against B and F HIV-1 infection, with a slightly more probable effectiveness for F than B genotype. Although the Bbr variant appears to induce a much more specific humoral immune response, the susceptibility in neutralizing the Brazilian HIV-1 B genotype Bbr variant is similar to that observed with the classical B genotype HIV-1.